Last reviewed · How we verify

NCT05551468: StayFine

StayFine: Personalised Relapse Prevention of Anxiety and Mood Disorders in Youths

Active, enrolled NA Last updated 5 December 2024
What this trial tests

NA trial testing StayFine guided app-based personalised intervention modules in Depressive Disorder in 254 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline
16 December 2019
Primary endpoint
21 November 2027
21 November 2027

Quick facts

Lead sponsorGgz Oost Brabant
PhaseNA
StatusActive, enrolled
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposeprevention
Enrollment254
Start date16 December 2019
Primary completion21 November 2027
Estimated completion21 November 2027
Sites1 location across Netherlands

Drugs / interventions tested

Conditions studied

Sponsor

Ggz Oost Brabant

Who can join

Adults 13 to 21, any sex, with Depressive Disorder or Anxiety Disorders. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The current study examines the effectiveness of the StayFine app for relapse prevention of anxiety or depressive disorders in youth using a randomized controlled trial. In addition, ecological momentary assessment (EMA) is used to explore fluctuations in emotions, psychological factors as predictor of the intervention effect and potential differential mechanisms of change. A total of 254 healthy youths remitted from an anxiety and/or depressive disorder, aged 13-21 years old, will be recruited for the study. Participants will be randomized to either 1) use the StayFine app exclusively for monitoring, or 2) use the StayFine app for monitoring and interventions supported by an expert patient. Stratification blocks are of random size and depend on previous episodes (1/2/3 or more) and previous treatment (yes/no). The intervention is based on the well-established Preventive Cognitive Therapy (PCT) for relapse prevention for adults and Cognitive Behavioral therapy adapted for the relapse prevention phase, both supplemented for anxiety and adolescents. In both conditions adolescents monitor their symptoms five times in three years and feedback and treatment advice is given in case of relapse. The primary outcome will be time to relapse. Secondary outcomes are (core) symptoms of depression and anxiety, number and duration of relapses, global functioning and quality of life. Mediators and moderators will be explored. Exploratory endpoints are monitoring and wearable outcomes.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Personalised app-based relapse prevention of depressive and anxiety disorders in remitted adolescents and young adults: a protocol of the StayFine RCT.
    Robberegt SJ, Kooiman BEAM, Albers CJ, Nauta MH, et al · · 2022 · cited 6× · PMID 36521888 · DOI 10.1136/bmjopen-2021-058560
  2. Examining varying number of intervention-modules and change in individual networks in young people remitted from depression or anxiety: Exploratory outcomes of the StayFine randomized clinical trial.
    Robberegt SJ, Albers CJ, Kooiman BEAM, Vuuregge AH, et al · · 2026 · PMID 42181993 · DOI 10.1016/j.nsa.2026.107007

Verify or expand the search:

Other recruiting trials for Depressive Disorder

Currently open trials in the same condition.

Other Ggz Oost Brabant trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05551468.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing